These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21102415)

  • 1. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.
    Schlumbrecht MP; Xie SS; Shipley GL; Urbauer DL; Broaddus RR
    Mod Pathol; 2011 Mar; 24(3):453-62. PubMed ID: 21102415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP60 predicts survival in advanced serous ovarian cancer.
    Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
    Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma.
    Bakkar RM; Xie SS; Urbauer DL; Djordjevic B; Vu K; Broaddus RR
    Int J Gynecol Pathol; 2015 Nov; 34(6):497-506. PubMed ID: 26166715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
    Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
    Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
    Darb-Esfahani S; Wirtz RM; Sinn BV; Budczies J; Noske A; Weichert W; Faggad A; Scharff S; Sehouli J; Oskay-Ozcelik G; Zamagni C; De Iaco P; Martoni A; Dietel M; Denkert C
    Endocr Relat Cancer; 2009 Dec; 16(4):1229-39. PubMed ID: 19675076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
    Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
    Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
    Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
    J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
    BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
    Romeo M; Karachaliou N; Chaid I; Queralt C; De Aguirre I; Del Carmen Gómez M; Sanchez-Ronco M; Radua J; Ramírez JL; Rosell R
    Int J Biol Markers; 2017 Mar; 32(1):e90-e95. PubMed ID: 27443420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
    McMillen BD; Aponte MM; Liu Z; Helenowski IB; Scholtens DM; Buttin BM; Wei JJ
    Mod Pathol; 2012 Dec; 25(12):1644-53. PubMed ID: 22790015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
    Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
    Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
    King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK
    Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.